Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model

Journal of Gene Medicine

Volumn 8, Issue 2, 2006, Pages 163-174

  Yoo, Jinsang ^a   Choi, Seeyoung ^a   Hwang, Kyung Sun ^a   Cho, Won Kyung ^a   Jung, Cho Rok ^a   Kwon, Suk Tae ^b   Im, Dong Soo ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Adeno associated virus vector; Apoptosis; Cancer gene therapy; Secretion; TRAIL

Indexed keywords

CASPASE 3; DISULFIDE; LEUCINE ZIPPER PROTEIN; OLIGOMER; PARVOVIRUS VECTOR; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; EXPERIMENTAL NEOPLASM; FEMALE; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE SEQUENCE; GENE TRANSFER; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PLASMID; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEIN SECRETION; TUMOR GROWTH; TUMOR REGRESSION; VALIDATION PROCESS;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CYSTINE; DEPENDOVIRUS; FEMALE; GENE THERAPY; GENETIC VECTORS; HEPATOCYTES; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS MUSCULUS; PARVOVIRUS;

EID: 32844465860     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.832     Document Type: Article

References (46)

1. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4: 333-339.
2. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22: 8628-8633.
3. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113.
4. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815-818.
5. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821.
6. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 5386-5397.
7. Wu GS, Burns TF, McDonald ER 3rd, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141-143.
8. Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813-820.
9. Marsters SA, Sheridan JP, Pitti RM, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7: 1003-1006.
10. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-14357.
11. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
12. Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7: 94-100.
13. Jelachich ML, Lipton HL. Theiler's murine encephalomyelitis virus induces apoptosis in gamma interferon-activated M1 differentiated myelomonocytic cells through a mechanism involving tumor necrosis factor alpha (TNF-alpha) and TNF-alpha-related apoptosis-inducing ligand. J Virol 2001; 75: 5930-5938.
14. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
15. Faubion WA, Gores GJ. Death receptors in liver biology and pathobiology. Hepatology 1999; 29: 1-4.
16. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
17. Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299: 31-38.
18. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564-567.
19. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-385.
20. Kim SH, Kim K, Kwagh JG, et al. Death induction by recombinant native TRAIL and its prevention by a caspase-9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 2004; 279: 40044-40052.
21. Leverkus M, Neumann M, Mengling T, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000; 60: 553-559.
22. Monahan PE, Samulski RJ. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 2000; 6: 433-440.
23. Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A 1984; 81: 6466-6470.
24. Tratschin JD, West MH, Sandbank T, et al. A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol 1984; 4: 2072-2081.
25. Snyder RO. Adeno-associated virus-mediated gene delivery. J Gene Med 1999; 1: 166-175.
26. Carter BJ. Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective. Mol Ther 2004; 10: 981-989.
27. Armeanu S, Lauer UM, Smirnow I, et al. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003; 63: 2369-2372.
28. Mohr A, Henderson G, Dudus L, et al. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Ther 2004; 11: 534-543.
29. Harbury PB, Kim PS, Alber T. Crystal structure of an isoleucine-zipper trimer. Nature 1994; 371: 80-83.
30. Wu X, He Y, Falo LD Jr, et al. Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein. Mol Ther 2001; 3: 368-374.
31. Zolotukhin S, Potter M, Hauswirth WW, et al. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 1996; 70: 4646-4654.
32. Cho WK, Seong YR, Lee YH, et al. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol Ther 2004; 10: 938-949.
33. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
34. Hauswirth WW, Lewin AS, Zolotukhin S, et al. Production and purification of recombinant adeno-associated virus. Methods Enzymol 2000; 316: 743-761.
35. Shetty S, Gladden JB, Henson ES, et al. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFB activation in epithelial derived cell lines. Apoptosis 2002; 7: 413-420.
36. Marsters SA, Pitti RM, Donahue CJ, et al. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol 1996; 6: 750-752.
37. Tanaka S, Sugimachi K, Shirabe K, et al. Expression and antitumor effects of TRAIL in human cholangiocarcinoma. Hepatology 2000; 32: 523-527.
38. Yoo J, Choi S, Hwang KS, et al. Antitumor activity of AAV-2 vector encoding modified TRAIL gene. Mol Ther 2004; 9(suppl. 1): 364.
39. Kim MH, Billiar TR, Seol DW. The secretable form of trimeric TRAIL, a potent inducer of apoptosis. Biochem Biophys Res Commun 2004; 321: 930-935.
40. Shi J, Zheng D, Liu Y, et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005; 65: 1667-1692.
41. Ma H, Liu Y, Liu S, et al. Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. Int J Cancer 2005; 116: 314-321.
42. Bodmer JL, Meier P, Tschopp J, et al. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem 2000; 275: 20632-20637.
43. Mongkolsapaya J, Grimes JM, Chen N, et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 1999; 6: 1048-1053.
44. Koeberl DD, Alexander IE, Halbert CL, et al. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci U S A 1997; 94: 1426-1431.
45. Fu H, Muenzer J, Samulski RJ, et al. Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther 2003; 8: 911-917.
46. Zhong L, Chen L, Li Y, et al. Self-complementary adeno-associated virus 2 (AAV)-T cell protein tyrosine phosphatase vectors as helper viruses to improve transduction efficiency of conventional single-stranded AAV vectors in vitro and in vivo. Mol Ther 2004; 10: 950-957.